Ontology highlight
ABSTRACT: Background
The efficacy and safety of enfortumab vedotin combined with pembrolizumab (EV-PEMB) was investigated as a first-line treatment for advanced urothelial carcinoma (UC) in a phase III clinical trial (EV-302). The trial findings indicated significant prolonged progression-free survival (PFS) and overall survival (OS) compared to chemotherapy with a favorable safety profile. However, EV-PEMB is costly and it is unknown whether it is cost-effective compared to chemotherapy. This study aimed to conduct a cost-effectiveness analysis of EV-PEMB versus chemotherapy as a first-line treatment for advanced UC from the perspective of the Chinese healthcare system.Methods
A Markov model with three distinct health states was developed to assess the cost-effectiveness of E
SUBMITTER: You M
PROVIDER: S-EPMC11464446 | biostudies-literature | 2024
REPOSITORIES: biostudies-literature